Rituximab Biosimilar, N297A Mutant | C010P.NA

Catalog No.	C010P.NA
Product Name	Rituximab Biosimilar, N297A Mutant | C010P.NA
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Anti-CD20 Chimeric Monoclonal Antibody
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Source/Host	The monoclonal antibody rituximab biosimilar was produced in the Rituximab biosimilar CHO stable cell line.
Specificity/Sensitivity	The monoclonal antibody rituximab biosimilar specifically binds to the human TNF alpha.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by rituximab.
Form Of Antibody	0.2 uM filtered solution, pH 6.5, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Rituximab Biosimilar, N297A Mutant is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade rituximab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Rituximab biosimilar CHO stable cell line is available for licensing to manufacture the rituximab biosimilar protein.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C010P.NA: Rituximab Biosimilar, N297A Mutant

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues.

Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.

Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)

Please remember our product information: Rituximab Biosimilar, N297A Mutant: C010P.NA Syd Labs

No more offers for this product!